Key Takeaways
- Record revenue, margin split: FY25 revenue hit an all-time high with +20.5% YoY growth, but Q4 EBITDA margin compressed 183 bps as employee and R&D costs rose.
- Teva plant is the swing factor: The acquired facility is trending at a ₹400 crore run-rate in early Q1 FY26, and its ramp-up will determine both the revenue trajectory and the promised operating leverage.
- Tariff stance is pass-through: Management expects any tariff above 10% to be passed to customers, calling the policy unsustainable, while noting no prebuy occurred and April saw a slowdown from pricing uncertainty.
- Growth ambition is explicit but unguaranteed: Management is aiming for ~18% corporate topline growth over the next 3 years and ₹3,000 crore revenue in FY26, yet declined to call the 3-year target a formal projection.
- What to watch next quarter: Whether the Teva plant utilization actually hits 50% of capacity within 6 months, the trajectory of the 70 planned product launches, and any concrete M&A progress in Europe after the last deal fizzled.
Teva Facility Ramp-Up
- Current run-rate: In Q1 FY26 so far, the plant is trending at ~35 crore tablets, equivalent to a ₹400 crore annual revenue run-rate, roughly half the ₹800 crore capacity target.
- Utilization timeline: Management expects to hit 50% of the 800 crore unit capacity within the next 6 months, with full ramp-up toward the latter half of FY26 or early next year.
- Revenue trajectory: On a trend basis, the facility will hit a minimum ₹500-odd crores, moving toward ₹600-700 crores in the latter part of the year, with an eventual path to ₹1,000 crores requiring further CAPEX and debottlenecking.
- Operating leverage delayed: The under-leveraging of the Teva plant has kept SG&A elevated; utilization increases expected in H2 FY26 should bring operating leverage benefits, with management targeting 21-22% EBITDA margin once leverage materializes.
- Approvals took longer: Site variations and regulatory approvals for the acquired facility took more time than expected, delaying the ramp-up despite the ₹175-odd crore CAPEX already invested.
Mark Saldanha: "Today, not in the last quarter, not in the fourth quarter, but in the first quarter, we are trending around at Rs. 400 crores, which is pretty much half of what we had spoken of Rs. 800 crores coming out of the plant."
U.S. Market & Tariff Exposure
- U.S. growth engine: The U.S. market grew 34.7% YoY in FY25, driven by market share gains from existing products, new product launches, and new retail outlets, all from an extremely small base relative to the total addressable market.
- No tariff prebuy: There was no stock-up in March or April ahead of potential tariffs; instead, a slowdown occurred because of pricing uncertainty and recession concerns, and retailers cannot hold excess inventory across 10,000-20,000 SKUs.
- April conditions: April was similar to March, but conditions improved toward month-end when the tariff pause was announced.
- Pass-through mechanics: If tariffs are negligible, the company may absorb them through cost reductions; if 10% or above, management will work on passing them down, arguing that U.S. domestic manufacturers also face raw material import tariffs from China, so the competitive gap may not widen materially.
- Force majeure: Tariffs are considered a force majeure event not covered by existing contracts, and retailers have already made public statements that prices will rise as non-tariff inventory depletes.
Mark Saldanha: "If it is extremely negligible and insignificant, we may not bother burdening anything, probably try to get the cost of goods down to nullify it. But most likely, if it is 10% or anything above 10%, we will definitely work on passing it down."
Margins & Cost Structure
- Q4 margin compression: EBITDA margin fell 183 bps to 17.8% in Q4, driven by higher employee expenses from headcount additions at the Goa facility and increased R&D spend, partially offset by a 228 bps gross margin expansion to 54.1% from better product mix and lower raw material costs.
- Full-year margin: FY25 EBITDA margin declined 90 bps to 20.2%, with employee costs, elevated freight in H1, and higher R&D as the main drags.
- Freight normalization: Freight costs were 5% of sales in FY25 versus 4% in FY24, concentrated in the first two quarters; costs have already moderated and are expected to return to 4% in FY26.
- R&D steady-state: R&D expenditure is expected to remain between 1.9% and 2.0% of revenue on a year-on-year basis.
- Hiring near peak: The company is very close to peak hiring, with only marginal additions required going forward, extremely small relative to the last quarter's quantum.
- Working capital range: Inventory has risen to support new U.S. launches, requiring 3-4 months of stock at any point; working capital is expected to stay within 125 to 135 days.
Mark Saldanha: "I do believe we will maintain our EBITDA, our historic EBITDA that we have done but improve on that."
Product Pipeline & Commercialization
- Launch cadence: 58 SKUs were commercialized during FY25, with approximately 79 more products in the pipeline; management plans to launch very close to 70 products between now and September across cold, digestive, pain, and some prescription segments.
- Order book execution: The $22 crore order book will be executed in FY26, with shipments starting around September in a trending pattern rather than all at once.
- Order book ambition: Management is targeting a $300 million order book status within the next 2 years.
- U.K. pipeline: Approval was received for ~12 products in the U.K., with 18 additional products already filed; management has a very aggressive growth plan for the U.K. market, with numbers expected to unfold in a couple of years.
- OTC skew: The OTC segment crossed ₹2,000 crore in FY25, and management expects OTC may grow to 85% of total revenues over time.
Geographic & M&A Strategy
- European M&A stalled: The company was in dialogue for European acquisitions, but those discussions fizzled out in the last 10 days; management continues to pursue European targets with mandates given, each in the €30-40 million range.
- Cash reserved for deals: Approximately ₹400-odd crores is kept aside for M&A and CAPEX; the company remains debt-free, and working capital will rise with the aggressive growth strategy.
- European market entry: Europe is still a new target market, and the company is focusing more on those markets now than ever before.
- India entry aspirational: Management hopes to enter the Indian market someday, but no timeline or concrete plan was provided.
- Capacity beyond 2 years: The company will likely need to add facilities after 2 years and is always on the lookout, but nothing concrete is under discussion today.
Mark Saldanha: "In pharma, you have got to invest today to see returns after 2 years. So technically, we are always on the lookout for facility expansion."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue target | ₹3,000 crores revenue (from ₹2,600 crores in FY25) | FY26 |
| Corporate growth rate | 17.5% to 18% year-on-year topline growth | FY26 and aiming for next 3 years |
| U.S. growth rate | 25% plus year-on-year | FY26 and next couple of years |
| Teva plant utilization | Hit 50% of 800 crore unit capacity | Within next 6 months |
| Teva plant full ramp | Ramp to 800 crore units | Latter half of FY26 or early next year |
| Teva plant revenue | Minimum ₹500-odd crores, trending toward ₹600-700 crores | Latter part of FY26 |
| EBITDA margin | Maintain historic levels and improve; 21-22% once operating leverage materializes | FY26 and as Teva utilization rises |
| R&D expenditure | 1.9% to 2.0% of revenue | Year-on-year basis |
| CAPEX | $8 million to $10 million overall | FY26 |
| Freight cost | Return to 4% of sales | FY26 |
| Working capital | 125 to 135 days | Ongoing |
| Product launches | ~70 products across cold, digestive, pain, prescription segments | Between now and September |
| Order book execution | $22 crore order book shipped in trending pattern starting September | FY26 |
| Order book target | $300 million status | Within next 2 years |
| Tariff pass-through | Pass down to customers if 10% or above | If and when implemented |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Operating revenue | ₹708.5 cr, +26.5% YoY |
| U.S. and North America revenue | ₹328.6 cr, +34.1% YoY |
| U.K. and EU formulation revenue | ₹274.1 cr, +17.7% YoY |
| Australia and New Zealand revenue | ₹76.5 cr, +20.9% YoY |
| Rest of world revenue | ₹29.3 cr, +55% YoY |
| Gross margin | 54.1%, +228 bps YoY |
| EBITDA | ₹125.8 cr, +14.7% YoY |
| EBITDA margin | 17.8%, -183 bps YoY |
| Profit after tax | ₹90.7 cr, +16.9% YoY |
| EPS | ₹2 |
| R&D spend | ₹23.47 cr, up from ₹11.71 cr in Q3 FY25 |
| Teva facility volumes | ~20 crore units, trending at ~35 crore tablets in early FY26 |
| Other facilities capacity utilization | ~65% |
| Working capital cycle | 127 days |
| Order book | $22 crore (₹220 cr), targeting $300 million within 2 years |
| Freight cost as a percentage of sales | 5% in FY25, expected to return to 4% in FY26 |